• New York federal court confirmed an arbitration award against Sun Pharma tied to Absorica LD’s Canada launch and disputed clinical data ownership.
• Sun’s bid to partially vacate the award was denied; Cipher’s cross-petition to confirm the award was granted.
• Award includes CAD 4.24 million damages, a 15% royalty on Canada net sales from Jan. 1, 2026 through Dec. 31, 2040.
• Court added 9% annual interest from the award date to judgment, plus post-judgment interest until payment is satisfied.
• Company plans to pursue additional claims over alleged use of its clinical data in other jurisdictions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cipher Pharmaceuticals Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202609011700CANADANWCANADAPR_C8003) on September 01, 2026, and is solely responsible for the information contained therein.